Progress in inflammatory bowel disease.
During the past 20 years, advances have been made in Crohn's disease and chronic ulcerative colitis. Despite impressive progress, it is still necessary to call these diseases 'idiopathic', as the details of their etiology remain obscure. Four areas will be reviewed in this article: genetics; intestinal inflammation; the relationship between the gut flora and the mucosa; and medical therapy.
Singleton
John W
JW
University of Colorado Health Sciences Center, Denver, Colorado, USA. xcdoc@aol.com
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics / Q000382:microbiology / Q000473:pathology; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000382:microbiology / Q000473:pathology; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics; D053473:Nod2 Signaling Adaptor Protein
D000911:Antibodies, Monoclonal; D047908:Intracellular Signaling Peptides and Proteins; C429018:NOD2 protein, human; D053473:Nod2 Signaling Adaptor Protein; D000069285:Infliximab